Inflammatory Bowel Disease 28 (IBD28) Cell Models for Research

Inflammatory Bowel Disease 28 (IBD28) is a rare monogenic form of inflammatory bowel disease (IBD) with an autosomal recessive inheritance pattern. It is caused by mutations in the IL10RA gene, which encodes the alpha subunit of the interleukin-10 receptor. The exact global incidence is unknown, but it is extremely rare, with only a few hundred cases reported worldwide. The disease typically presents in infancy or early childhood with severe enterocolitis, perianal disease, and failure to thrive. Without treatment, the condition is life-threatening, with high morbidity and mortality. Early diagnosis and hematopoietic stem cell transplantation can be curative, but many patients die in infancy if untreated. The disease is a model for studying the role of IL-10 signaling in intestinal homeostasis and inflammation.

IBD28 provides a unique opportunity to study the fundamental mechanisms of intestinal inflammation and immune regulation. Because it is a monogenic disease, it offers a clear genetic cause that can be precisely modeled in vitro and in vivo. Researchers can use gene-edited cell lines to dissect the IL-10 signaling pathway, identify downstream targets, and test potential therapeutic interventions. The disease also serves as a paradigm for other inflammatory disorders, making it a valuable model for drug discovery and functional genomics.

The primary pathway affected in IBD28 is the IL-10 signaling pathway. IL-10 is an anti-inflammatory cytokine that signals through a receptor complex composed of IL10RA and IL10RB subunits. The signaling cascade involves:

1. IL-10 binding to the IL-10 receptor complex.

2. Activation of JAK1 and TYK2 kinases.

3. Phosphorylation and activation of STAT3.

4. Translocation of STAT3 to the nucleus to regulate transcription of anti-inflammatory genes.

Loss-of-function mutations in IL10RA disrupt this pathway, leading to uncontrolled inflammation in the gut. Additionally, impaired IL-10 signaling affects the function of regulatory T cells and macrophages, contributing to the severe inflammatory phenotype.

Data from ClinVar and NCBI Gene indicate that mutations in IL10RA are the sole cause of IBD28. The most common mutations are missense variants that affect protein stability or ligand binding, but null mutations also occur.

The IL-10 signaling pathway is central, but its disruption affects multiple downstream networks:

• • JAK-STAT pathway: Impaired STAT3 activation leads to reduced expression of anti-inflammatory cytokines (e.g., IL-10 itself, IL-1RA) and increased pro-inflammatory cytokines (e.g., TNF-alpha, IL-6).
• • NF-kB pathway: Loss of IL-10 signaling enhances NF-kB activity, promoting inflammation.
• • T-cell regulation: Regulatory T cell function is compromised, leading to effector T cell activation.
• • Macrophage function: Macrophages become hyperresponsive to inflammatory stimuli, producing excessive inflammatory mediators.

These networks are interconnected, and their dysregulation contributes to the chronic inflammation seen in IBD28.

Organoids derived from patient intestinal biopsies or engineered from pluripotent stem cells offer a more physiologically relevant model. They recapitulate the intestinal epithelium and can be used to study the impact of IL10RA mutations on barrier function and inflammation.

• • IL10 knockout mice: Develop spontaneous colitis, mimicking IBD symptoms.
• • IL10RA knockout mice: Show severe intestinal inflammation, similar to human IBD28.
• • IL10RA mutant mice (e.g., point mutations): Useful for studying specific mutations.
• • Patient-derived xenografts (PDX): Not commonly used for IBD28 due to the immune component, but can be used for tumor models if applicable.
• • Induced models: Chemical induction (e.g., DSS-induced colitis) can be used in wild-type mice to study inflammation, but they do not replicate the genetic defect.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with specific IL10RA mutations. For example:

• • IL10RA knockout cell lines: Complete loss of function, mimicking null mutations.
• • IL10RA point mutation knock-in lines: Introduce specific missense mutations (e.g., p.T84I, p.G141R) to study their functional impact.

These gene-edited models are sequence-verified and commercially available from various sources. They are essential for studying the molecular consequences of IBD28 mutations, screening therapeutic compounds, and validating gene therapy approaches. Using isogenic pairs (wild-type vs. mutant) eliminates genetic background variability, allowing precise attribution of phenotypic differences to the mutation.

Gene-edited cell lines are used to validate the functional impact of IL10RA mutations. For example:

• • Knockout of IL10RA in THP-1 cells leads to increased TNF-alpha production upon LPS stimulation, confirming the anti-inflammatory role of IL-10 signaling.
• • Knock-in of a specific mutation (e.g., p.T84I) can be compared to wild-type to assess the effect on STAT3 phosphorylation and downstream gene expression.

These models help identify novel downstream targets and pathways that may be exploited for therapeutic intervention.

Isogenic cell line pairs (wild-type vs. IL10RA mutant) are valuable for high-throughput screening of anti-inflammatory compounds. For example:

• • Screen for small molecules that can bypass the defective IL-10 signaling and suppress inflammation.
• • Test biologics such as anti-TNF antibodies or IL-10 mimetics for efficacy in the mutant background.
• • Study resistance mechanisms: If a drug requires functional IL-10 signaling, mutant cells will be resistant, helping to identify drugs that work independently of this pathway.

CRISPR-based synthetic lethality screens can identify genes that are essential for survival in IL10RA-mutant cells but not in wild-type cells. These genes could serve as novel therapeutic targets. Additionally, gene-edited cells can be used to discover biomarkers of disease activity by comparing the secretome or transcriptome of mutant vs. wild-type cells under inflammatory conditions.